PUREfi Wealth LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

PUREfi Wealth LLC increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 82.3% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,285 shares of the company's stock after acquiring an additional 580 shares during the period. Eli Lilly and Company makes up about 1.1% of PUREfi Wealth LLC's holdings, making the stock its 15th largest holding. PUREfi Wealth LLC's holdings in Eli Lilly and Company were worth $1,061,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Kingswood Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 5.7% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 9,254 shares of the company's stock worth $7,591,000 after purchasing an additional 497 shares during the period. Essex Savings Bank boosted its stake in Eli Lilly and Company by 9.1% during the first quarter. Essex Savings Bank now owns 12,061 shares of the company's stock worth $9,961,000 after buying an additional 1,007 shares during the period. Puzo Michael J increased its position in shares of Eli Lilly and Company by 288.1% during the first quarter. Puzo Michael J now owns 2,542 shares of the company's stock valued at $2,099,000 after acquiring an additional 1,887 shares during the last quarter. Pegasus Asset Management Inc. raised its stake in shares of Eli Lilly and Company by 2.4% in the 1st quarter. Pegasus Asset Management Inc. now owns 5,228 shares of the company's stock valued at $4,318,000 after acquiring an additional 124 shares during the period. Finally, Hoge Financial Services LLC lifted its holdings in shares of Eli Lilly and Company by 18.4% in the 1st quarter. Hoge Financial Services LLC now owns 438 shares of the company's stock worth $362,000 after acquiring an additional 68 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.9%

Shares of NYSE:LLY traded down $6.96 during trading hours on Thursday, reaching $784.28. The stock had a trading volume of 2,441,727 shares, compared to its average volume of 3,656,357. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The firm's 50 day moving average is $778.55 and its 200-day moving average is $801.58. The stock has a market capitalization of $743.29 billion, a price-to-earnings ratio of 63.81, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.58 earnings per share. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research reports. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.